In America’s 250th year, we are hosting the World Cup and asking whether 2026 might finally be the year we solve two of our most stubborn problems: soccer and healthcare. The optimism is classically American: loud, infectious, and only loosely connected to the historical record. The follow-through is where it gets interesting. Healthcare is telling the same story it always tells: big promise, real talent, and a finish that’s harder than it looks.
Just recently, HHS launched Operation Trialblazer. FDA is looking to shorten the road to first-in-human trials. UnitedHealth just committed $3 billion to AI to take $1 billion out of operating costs this year. Big promise from real talent. The scoreboard tells a different story: CMS projects $9 trillion in national healthcare spending by 2034, and only 49% of U.S. adults can currently afford consistent care, a five-year low.
GRAIL’s investor lawsuit is the latest cautionary tale. Investors allege executives assured markets the NHS-Galleri trial would prove meaningful cancer detection. It didn’t. Overselling the fireworks before anyone sees the show is a proud American tradition, and diagnostics is not immune. A test can be FDA-cleared, commercially polished, and clinically plausible and still not deliver. They don’t play the World Cup on paper and you don’t prove a test in a press release.
That gap between what looks promising and what actually holds up runs through the latest prior authorization stories, too. OIG found 95% of appealed MA skilled nursing facility denials got overturned. NaviHealth denied 14% of SNF requests, 97% of which were reversed on appeal. That is hard to defend as targeted management and increasingly hard for policymakers to ignore. The WISeR AI prior auth pilot is drawing fire from House Democrats, providers, and patients simultaneously. Not necessarily partisan noise, but rather convergent pressure from every direction.
And it wouldn’t be a week in healthcare without touching on AI, which is producing real results alongside the ever-present hype. OpenAI’s o3 improved diagnostic yield in previously unresolved rare disease cases. Pathway Labs got FDA clearance for a cardiac AI tool that outperformed cardiologists in structural heart disease detection. Both are real. At the same time, state AGs opened an investigation into OpenAI’s health data practices less than a week after the company filed to go public. The promise is real. So are the questions.
This Week’s Key Developments
- CMS projects $9 trillion in national healthcare spending by 2034
Retail prescription drugs, particularly GLP-1s and high-cost oncology medications, are the fastest-growing category in the near term. The uninsured rate is projected to climb from 8.2% to 9.5% by 2034. More coverage gaps, more cost pressure, less margin for error. - CLFS activity continues as diagnostics expand across care categories
CMS held its CY 2027 CLFS public meeting in June, with Advisory Panel payment recommendations due July 14-15. Meanwhile, FDA approvals, NCCN guideline updates, and AI-enabled tools are pushing diagnostics deeper into oncology, cardiology, Alzheimer’s, and rare disease before payment policy has caught up. - Prior authorization is under pressure from every direction
OIG flagged improper MA post-acute denials with a 95% SNF appeal overturn rate. House Democrats demanded data from the WISeR AI prior auth pilot. ACLA called on CMS to prohibit denials when prior auths are submitted after specimen collection. The message is getting louder: plans will need to show their work.
Strategic Takeaway
Diagnostics and lab management are where a lot of this week’s pressure shows up first. New tools, rising costs, prior auth fights, and AI all beg the same basic question: what is proven enough to use, cover, and defend? Innovation continues to move faster than both evidence development and payment policy, and that gap is where the risk accumulates. For health plans, the answer requires more than optimism. It requires knowing the difference between a real advance and an expensive highlight reel before the bill comes due.
Two hundred and fifty years in, optimism is still easier to build than discipline. And discipline is what gets paid for.
